In this review:
CHIP is associated with reduced Alzheimer disease risk
Fitusiran prophylaxis in haemophilia A or B
DUSP6 mediates resistance to JAK2 inhibition and drives MPN progression
Ruxolitinib before during and after SCT in primary or secondary myelofibrosis
Haplo- vs. matched unrelated donor SCT with post-transplant cyclophosphamide for lymphoma
Sabatolimab + hypomethylating agents in very high-/high-risk MDS and AML
Novel triplets for extending remission with venetoclax in elderly AML
Pegcetacoplan in complement inhibitornaïve patients with PNH
Rilzabrutinib in relapsed/refractory ITP
Splenectomy for primary ITP in the thrombopoietin receptor agonist era
Please login below to download this issue (PDF)